Jul 13, 2026 09:01AM
Jul 13, 2026 09:00AM
Jun 30, 2026 08:00PM
Jun 30, 2026 08:00PM
Jun 24, 2026 08:01AM
Jun 24, 2026 08:00AM
Jun 18, 2026 09:01AM Cadrenal plans FDA rare pediatric disease filing for tecarfarin
Jun 18, 2026 09:00AM
Jun 15, 2026 08:30AM
Jun 15, 2026 08:30AM
Jun 3, 2026 09:02AM
Jun 3, 2026 09:00AM
May 19, 2026 04:30PM
May 7, 2026 08:30AM Cadrenal Therapeutics receives FDA guidance for CAD-1005 phase 3 trial
May 7, 2026 08:30AM
Apr 30, 2026 08:30AM
Apr 30, 2026 08:30AM
Mar 31, 2026 08:45AM
Mar 31, 2026 08:45AM
Mar 12, 2026 08:00AM
Mar 2, 2026 08:01AM Cadrenal Therapeutics schedules regulatory meeting for HIT drug
Mar 2, 2026 08:00AM
Feb 24, 2026 08:30AM
Feb 24, 2026 08:30AM
Jan 12, 2026 08:02AM
Jan 12, 2026 08:00AM
Dec 11, 2025 08:05AM
Dec 11, 2025 08:05AM Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)
Aug 5, 2025 06:01AM
Aug 5, 2025 06:00AM
May 8, 2025 08:00AM
Mar 13, 2025 04:05PM
Jan 9, 2025 08:44AM
Dec 31, 2024 08:00AM
Nov 12, 2024 09:00AM CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS
Nov 7, 2024 09:00AM
Aug 22, 2024 09:03AM
Aug 22, 2024 09:00AM
Aug 20, 2024 09:00AM
Aug 14, 2024 09:00AM
Aug 7, 2024 04:05PM
Aug 6, 2024 09:00AM Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs
Jul 17, 2024 09:00AM
Jun 11, 2024 04:15PM
Jun 3, 2024 09:00AM
May 23, 2024 09:00AM
May 9, 2024 09:00AM
Apr 11, 2024 04:30PM
Apr 9, 2024 09:05AM Cadrenal Therapeutics (CVKD) Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total
Apr 9, 2024 09:00AM

325,869 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All